Zydus receives tentative approval from USFDA for Sugammadex Injection
Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery
Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery
The policy aspires to reduce cost of logistics in India to be comparable to global benchmarks by 2030
These moves are designed to strengthen the company’s medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales, and delivery to delight customers
Veda Corporate Advisors was the exclusive financial advisor to SHPL and its shareholders.
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India
The Department of Health and Family Welfare updated the preparedness for transition to licensing of Class-A and Class-B medical devices with effect from 1st October, 2022 under Medical Devices Rules 2017
Cariprazine is an atypical antipsychotic indicated for the treatment of schizophrenia and acute treatment of manic or mixed episodes associated with bipolar I disorder
Pfizer’s Paxlovid is approved by US FDA for COVID treatment
Investment further strengthens Merck's "Big 3," the key drivers for increasing Group sales to approximately € 25 billion by 2025
The OAI classification implies that the USFDA expects further corrective actions and may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved
Subscribe To Our Newsletter & Stay Updated